{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:18:23Z","timestamp":1788265103586,"version":"build-2803163510"},"reference-count":41,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    <jats:bold>Background &amp; aim:<\/jats:bold>\n                    Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can lead to increased morbidity and mortality. This study described real-world treatment patterns and clinical outcomes by line of treatment among patients with PBC in the US.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Adults (\u226518\u00a0years) diagnosed with PBC on or after 1 January 17 were identified in the IQVIA PharMetrics\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Plus database and grouped into newly diagnosed, first-line (1L) and second-line or more (2L+) cohorts. Index date was initial PBC diagnosis or initiation of 1L or 2L therapy; follow-up continued until the earliest of end of continuous enrollment, death or data end. Time to treatment initiation, treatment discontinuation and negative clinical outcomes were assessed with Kaplan\u2013Meier analysis.\n                    <jats:bold>Results:<\/jats:bold>\n                    The newly diagnosed, 1L and 2L+ cohorts included 1748, 1659 and 181 patients, respectively (average age at index: 52.7\u201354.5\u00a0years; female: 84.2\u201389.0%). Of the newly diagnosed cohort, 34.8% did not initiate PBC treatment within 1.5\u00a0years post-diagnosis. In the 1L cohort, median time from diagnosis to 1L initiation was 1.2\u00a0months; median time from 1L initiation to 1L discontinuation\/2L initiation was nearly 5\u00a0years. In the 2L+ cohort, median time from 2L initiation to 2L discontinuation was approximately 4\u00a0years. In the untreated, 1L, and 2L+ cohorts, 18.9%, 14.4% and 19.3% of patients developed \u22651 negative clinical outcome post-index (usually cirrhosis).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Results of this US population-based study demonstrate a potential unmet need for early intervention and effective treatment options for patients with PBC, as one in three patients with PBC remain untreated years after diagnosis.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0172","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:53:11Z","timestamp":1786535591000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-7786","authenticated-orcid":false,"given":"Nisreen","family":"Shamseddine","sequence":"first","affiliation":[{"name":"Ipsen, Cambridge, MA 02142, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-8418","authenticated-orcid":false,"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA 02199, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-8838","authenticated-orcid":false,"given":"Su","family":"Zhang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA 02199, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-0636","authenticated-orcid":false,"given":"Dongni","family":"Ye","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA 02199, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-7121","authenticated-orcid":false,"given":"Shravanthi","family":"Seshasayee","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA 02199, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0141-2241","authenticated-orcid":false,"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA 02199, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6873-6933","authenticated-orcid":false,"given":"Sonal","family":"Kumar","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, Cornell University, New York, NY 10065, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-3652","authenticated-orcid":false,"given":"Kris V","family":"Kowdley","sequence":"additional","affiliation":[{"name":"Liver Institute Northwest, Seattle, WA 98105, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_9_3_2","first-page":"49","article-title":"Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches","volume":"8","author":"Galoosian A","year":"2020","unstructured":"Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J. Clin. Transl. Hepatol. 8(1), 49\u201360 (2020).","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"8","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin. Gastroenterol. Hepatol. 16(8), 1342\u20131350 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114(1), 48\u201363 (2019).","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","article-title":"Primary biliary cholangitis: a comprehensive overview","volume":"11","author":"Lleo A","year":"2017","unstructured":"Lleo A, Marzorati S, Anaya JM, Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hepatol. Int. 11(6), 485\u2013499 (2017).","journal-title":"Hepatol. Int."},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69(1), 394\u2013419 (2019).","journal-title":"Hepatology"},{"issue":"4","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3350\/cmh.2012.18.4.375","article-title":"Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score","volume":"18","author":"Jung HE","year":"2012","unstructured":"Jung HE, Jang JY, Jeong SW Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score. Clin. Mol. Hepatol. 18(4), 375\u2013382 (2012).","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000506980","article-title":"Quality of life in patients with primary biliary cholangitis: a single-center experience in Serbia","volume":"38","author":"Milovanovic T","year":"2020","unstructured":"Milovanovic T, Popovic D, Stojkovic Lalosevic M Quality of life in patients with primary biliary cholangitis: a single-center experience in Serbia. Dig. Dis. 38(6), 515\u2013521 (2020).","journal-title":"Dig. Dis."},{"issue":"10","key":"e_1_3_9_10_2","first-page":"1840","article-title":"The natural history of abdominal pain associated with primary biliary cirrhosis","volume":"89","author":"Laurin JM","year":"1994","unstructured":"Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain associated with primary biliary cirrhosis. Am. J. Gastroenterol. 89(10), 1840\u20131843 (1994).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1572-0241.2006.00423.x","article-title":"Dermatological manifestations in primary biliary cirrhosis patients: a case control study","volume":"101","author":"Koulentaki M","year":"2006","unstructured":"Koulentaki M, Ioannidou D, Stefanidou M Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am. J. Gastroenterol. 101(3), 541\u2013546 (2006).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1111\/hepr.12978","article-title":"Prevalence of pruritus in patients with chronic liver disease: a multicenter study","volume":"48","author":"Oeda S","year":"2018","unstructured":"Oeda S, Takahashi H, Yoshida H Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol. Res. 48(3), E252\u2013E262 (2018).","journal-title":"Hepatol. Res."},{"issue":"1","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells GF","year":"2013","unstructured":"Mells GF, Pells G, Newton JL Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 58(1), 273\u2013283 (2013).","journal-title":"Hepatology"},{"issue":"6","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/2050640620919585","article-title":"Diagnosis and treatment of primary biliary cholangitis","volume":"8","author":"Laschtowitz A","year":"2020","unstructured":"Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol. J. 8(6), 667\u2013674 (2020).","journal-title":"United European Gastroenterol. J."},{"issue":"4","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince M","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123(4), 1044\u20131051 (2002).","journal-title":"Gastroenterology"},{"key":"e_1_3_9_16_2","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: URSO 250 & URSO FORTE (ursodiol). (Accessed 5 May 2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020675s028lbl.pdf"},{"key":"e_1_3_9_17_2","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: OCALIVA (obeticholic acid). (Accessed 5 May 2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207999s008lbl.pdf"},{"issue":"4","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor KD","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 75(4), 1012\u20131013 (2022).","journal-title":"Hepatology"},{"key":"e_1_3_9_19_2","unstructured":"Intercept Pharmaceuticals Inc. Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA). GlobeNewswire. (2024).https:\/\/www.einpresswire.com\/article\/759894865\/intercept-receives-complete-response-letter-from-fda-addressing-ocaliva-supplemental-new-drug-application-snda"},{"key":"e_1_3_9_20_2","unstructured":"Intercept Pharmaceuticals Inc. Intercept Announces Voluntary Withdrawal of OCALIVA\u00ae for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold. BioSpace. (2025). https:\/\/www.biospace.com\/press-releases\/intercept-announces-voluntary-withdrawal-of-ocaliva-for-primary-biliary-cholangitis-pbc-from-the-us-market-us-clinical-trials-involving-obeticholic-acid-placed-on-clinical-hold"},{"issue":"3","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot C","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48(3), 871\u2013877 (2008).","journal-title":"Hepatology"},{"issue":"8","key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.dld.2017.05.001","article-title":"Primary Biliary Cholangitis: advances in management and treatment of the disease","volume":"49","author":"Invernizzi P","year":"2017","unstructured":"Invernizzi P, Floreani A, Carbone M Primary Biliary Cholangitis: advances in management and treatment of the disease. Dig. Liver Dis. 49(8), 841\u2013846 (2017).","journal-title":"Dig. Liver Dis."},{"issue":"7","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375(7), 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem NS","year":"2015","unstructured":"Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology 62(2), 635\u2013643 (2015).","journal-title":"Hepatology"},{"key":"e_1_3_9_25_2","unstructured":"Gilead. Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA. Updated 14 August 2024. (Accessed 2 June 2026). https:\/\/www.gilead.com\/news\/news-details\/2024\/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda"},{"issue":"9","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield GM","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N. Engl. J. Med. 390(9), 783\u2013794 (2024).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_27_2","unstructured":"Ipsen. Ipsen's Iqirvo\u00ae receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis. Updated 10 June 2024. (Accessed 2 June 2026). https:\/\/www.ipsen.com\/press-release\/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis\/"},{"key":"e_1_3_9_28_2","unstructured":"GSK. Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC). Updated 19 March 2026. (Accessed 2 June 2026). https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/lynavoy-linerixibat-approved-by-the-us-fda\/"},{"issue":"1","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke III GR","year":"1996","unstructured":"Locke III GR, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 23(1), 52\u201356 (1996).","journal-title":"Hepatology"},{"issue":"6","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot C","year":"2000","unstructured":"Corpechot C, Carrat F, Bonnand A-M, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32(6), 1196\u20131199 (2000).","journal-title":"Hepatology"},{"issue":"2","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms MH","year":"2018","unstructured":"Harms MH, Lammers WJ, Thorburn D Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am. J. Gastroenterol. 113(2), 254\u2013264 (2018).","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12876-023-03108-4","article-title":"Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment","volume":"24","author":"MacDonald N","year":"2024","unstructured":"MacDonald N, Loh R, Fenkel JM, Sass DA, Halegoua-DeMarzio D. Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment. BMC Gastroenterol. 24(1), 18 (2024).","journal-title":"BMC Gastroenterol."},{"issue":"8","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Li J, Haller IV Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin. Gastroenterol. Hepatol. 16(8), 1333\u20131341.e6 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"e001287","DOI":"10.1136\/bmjgast-2023-001287","article-title":"Pruritus in primary biliary cholangitis is under-recorded in patient medical records","volume":"11","author":"Gungabissoon U","year":"2024","unstructured":"Gungabissoon U, Smith HT, von Maltzahn R Pruritus in primary biliary cholangitis is under-recorded in patient medical records. BMJ Open Gastroenterol. 11(1), e001287 (2024).","journal-title":"BMJ Open Gastroenterol."},{"issue":"2","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.23683","article-title":"The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice","volume":"52","author":"Al-Harthy N","year":"2010","unstructured":"Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology 52(2), 562\u2013570 (2010).","journal-title":"Hepatology"},{"issue":"10266","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo A","year":"2020","unstructured":"Lleo A, Wang G-Q, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet 396(10266), 1915\u20131926 (2020).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep4.1314","article-title":"Burden of primary biliary cholangitis among inpatient population in the United States","volume":"3","author":"Shahab O","year":"2019","unstructured":"Shahab O, Sayiner M, Paik J Burden of primary biliary cholangitis among inpatient population in the United States. Hepatol. Commun. 3(3), 356\u2013364 (2019).","journal-title":"Hepatol. Commun."},{"issue":"2","key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10620-019-05809-x","article-title":"Race\/ethnicity and insurance-specific disparities in in-hospital mortality among adults with primary biliary cholangitis: analysis of 2007\u20132014 national inpatient sample","volume":"65","author":"Galoosian A","year":"2020","unstructured":"Galoosian A, Hanlon C, Tana M, Cheung R, Wong RJ. Race\/ethnicity and insurance-specific disparities in in-hospital mortality among adults with primary biliary cholangitis: analysis of 2007\u20132014 national inpatient sample. Dig. Dis. Sci. 65(2), 406\u2013415 (2020).","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3748\/wjg.v19.i7.1111","article-title":"Risk factors for hepatic decompensation in patients with primary biliary cirrhosis","volume":"19","author":"Shi TY","year":"2013","unstructured":"Shi TY, Zhang LN, Chen H Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J. Gastroenterol. 19(7), 1111\u20131118 (2013).","journal-title":"World J. Gastroenterol."},{"key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bpg.2018.06.002","article-title":"Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)","volume":"34","author":"Janmohamed A","year":"2018","unstructured":"Janmohamed A, Trivedi PJ. Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Best Pract. Res. Clin. Gastroenterol. 34\u201335, 71\u201383 (2018).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"2","key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","article-title":"Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view","volume":"27","author":"Saturni S","year":"2014","unstructured":"Saturni S, Bellini F, Braido F Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm. Pharmacol. Ther. 27(2), 129\u2013138 (2014).","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"e_1_3_9_42_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jrsssa\/qnae039","article-title":"A framework for understanding selection bias in real-world healthcare data","volume":"187","author":"Kundu R","year":"2024","unstructured":"Kundu R, Shi X, Morrison J, Barrett J, Mukherjee B. A framework for understanding selection bias in real-world healthcare data. J. R. Stat. Soc. Ser. A Stat. Soc. 187(3), 606\u2013635 (2024).","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"issue":"10","key":"e_1_3_9_43_2","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1002\/pds.70013","article-title":"Identifying patients with primary biliary cholangitis and cirrhosis using administrative data in a national cohort","volume":"33","author":"John BV","year":"2024","unstructured":"John BV, Bastaich D, Dahman B, Veterans Analysis of Liver Disease Group of I. Identifying patients with primary biliary cholangitis and cirrhosis using administrative data in a national cohort. Pharmacoepidemiol. Drug Saf. 33(10), e70013 (2024).","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:45:42Z","timestamp":1788263142000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.57264\/cer-2025-0172"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0172","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"e250172"}}